Related Experiment Videos
Congestive heart failure: guidelines for the primary care physician
1Zena and Michael A. Wiener Cardiovascular Institute, Box 1030, Mount Sinai School of Medicine, One East 100th Street, New York, NY 10029, USA.
The Mount Sinai Journal of Medicine, New York
|September 12, 2003
Summary
Heart failure affects millions annually, costing billions. This review examines treatments like ACE inhibitors and beta blockers to improve patient outcomes and reduce disease progression.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure impacts nearly 5 million Americans yearly, with 500,000 new diagnoses.
- The disease incurs substantial societal and healthcare costs, estimated at $40 billion annually.
- Medications for heart failure alone account for approximately $500 million in annual spending.
Framework:
- Review of current treatment strategies for heart failure.
- Utilizes a patient case study to illustrate treatment application.
- Focuses on evidence-based data for medication efficacy.
Implementation:
- Discusses angiotensin-converting enzyme inhibitors (ACE inhibitors).
- Covers angiotensin receptor blockers (ARBs).
- Includes diuretics, digoxin, beta blockers, and spironolactone.
Implications:
- Aims to improve disease prevention and slow progression.
- Seeks to decrease morbidity and mortality rates.
- Focuses on optimizing patient quality of life through effective management.